Why the study?
Does subcutaneous low-molecular-weight heparin (LMWH) allow for safe and efficacious outpatient treatment compared to intravenous unfractionated heparin (UFH) in patients with venous thromboembolism?
Does subcutaneous low-molecular-weight heparin (LMWH) allow for safe and efficacious outpatient treatment compared to intravenous unfractionated heparin (UFH) in patients with venous thromboembolism?
Outpatient management of VTE with LMWH is safe, efficacious, and offers economic and convenience advantages over inpatient UFH.
May support outpatient LMWH consideration in uncomplicated VTE; leaves open need for updated RCTs before guideline changes.
Studies have shown subcutaneous low- molecular-weight heparin (LMWH) to be at least as safe and efficacious as intravenous unfractionated heparin (UFH) for the treatment of venous thromboembolism (VTE). Furthermore, unlike UFH, LMWH is administered on a once- or twice-daily basis without monitoring in uncomplicated cases. Consequently, it has been suggested that the large majority of patients with VTE could be treated on an outpatient basis. Exceptions include patients with an increased risk of haemorrhage, pregnant women, children and those with renal insufficiency. Outpatient management would offer economic advantages and be more convenient for both the patient and the hospital staff.
No takes yet. Share an insight, caveat, or question.
Per Lindmarker (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: